{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:57:56Z","timestamp":1773262676157,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-Therapy-Pneumonitis (PTP) is a critical side effect of both, thoracic radio(chemo)therapy (R(C)T) and immune checkpoint inhibition (ICI). However, disease characteristics and patient-specific risk factors of PTP after combined R(C)T\u2009+\u2009ICI are less understood. Given that RT-triggered PTP is strongly dependent on the volume and dose of RT [1], driven by inflammatory mechanisms, we hypothesize that combination therapy of R(C)T with ICI influences the dose-volume-effect correlation for PTP. This study focuses on the development of a method for evaluation of alterations of dosimetric parameters for PTP after R(C)T with and without ICI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and materials<\/jats:title>\n                    <jats:p>PTP volumes were delineated on the follow-up diagnostic Computed Tomography (CT) and deformably matched to the planning CT for patients with PTP after thoracic R(C)T\u2009+\u2009ICI or R(C)T. Dose data was converted to 2-Gy equivalent doses (EQD2) and dosimetrically analyzed. Dosimetric and volumetric parameters of the segmented PTP volumes were analyzed. The method was exemplarily tested on an internal patient cohort including 90 patients having received thoracic R(C)T\u2009+\u2009ICI (39) and R(C)T (51). Thirtytwo patients with PTP were identified for further analysis. Additional data on previous chemotherapy, RT, smoking status and pulmonary co-morbidity were conducted. A matched pair analysis with regard to planning target volumes (PTV) was conducted for curative intended (definitive) and palliative patient cohorts individually.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The presented method was able to quantify and compare the dosimetric parameters of PTP for the different therapies. For our study group, no significant differences between R(C)T\u2009+\u2009ICI and R(C)T only was observed. However, the dosimetric analysis revealed large volumetric fractions (55%) of the PTP volumes to be located outside of high dose (EQD2\u2009&lt;\u200940\u00a0Gy) regions for R(C)T\u2009+\u2009ICI. There was a non-significant trend towards increased area under the curve of the dose volume histogram (AUC) values for R(C)T\u2009+\u2009ICI compared to R(C)T only (3743.6\u00a0Gy\u2219% vs. 2848.8\u00a0Gy\u2219%;\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009=\u20090.171). In contrast to the data for the palliative intended treatment group, for definitive R(C)T\u2009+\u2009ICI, data tended towards increased volumes with higher doses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The proposed method was capable to quantify dosimetric differences in the dose-volume-effect relationship of PTP for patients with R(C)T\u2009+\u2009ICI and patients with R(C)T only. In this exploratory analysis, no significant dosimetric differences within PTP volumes for the different groups could be observed. However, our observations suggest, that for safe application of thoracic R(C)T\u2009+\u2009ICI, further careful investigation of dosimetric prescription and analysis concepts with larger and conformer study groups is recommendable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-024-02561-z","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T22:51:16Z","timestamp":1732229476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pneumonitis after normofractionated radioimmunotherapy: a method for dosimetric evaluation"],"prefix":"10.1186","volume":"19","author":[{"given":"Kim Melanie","family":"Kraus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Steinhelfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Feuerecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Cristina","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius Clemens","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai Joachim","family":"Borm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Caspar","family":"Peeken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie Elisabeth","family":"Combs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"2561_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12890-020-01376-4","volume":"21","author":"M Arroyo-Hern\u00e1ndez","year":"2021","unstructured":"Arroyo-Hern\u00e1ndez M, Maldonado F, Lozano-Ruiz F, Mu\u00f1oz-Monta\u00f1o W, Nu\u00f1ez-Baez M, Arrieta O. Radiation-induced lung injury: current evidence. BMC Pulm Med. 2021;21:9. https:\/\/doi.org\/10.1186\/s12890-020-01376-4.","journal-title":"BMC Pulm Med"},{"key":"2561_CR2","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379:2342\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1809697.","journal-title":"N Engl J Med"},{"key":"2561_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14737140.2023.2173175","volume":"23","author":"RR Colciago","year":"2023","unstructured":"Colciago RR, Fischetti I, Giandini C, La Rocca E, Rancati TT, Rejas Mateo A, et al. Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement. Expert Rev Anticancer Ther. 2023;23:135\u201345. https:\/\/doi.org\/10.1080\/14737140.2023.2173175.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2561_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/cancers10070222","volume":"10","author":"V Jain","year":"2018","unstructured":"Jain V, Berman AT. Radiation Pneumonitis: Old Problem, New tricks. Cancers (Basel). 2018;10:222. https:\/\/doi.org\/10.3390\/cancers10070222.","journal-title":"Cancers (Basel)"},{"key":"2561_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/s0360-3016(00)00783-5","volume":"49","author":"A Inoue","year":"2001","unstructured":"Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys. 2001;49:649\u201355. https:\/\/doi.org\/10.1016\/s0360-3016(00)00783-5.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2561_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13014-023-02278-5","volume":"18","author":"Z Gao","year":"2023","unstructured":"Gao Z, Zhao Q, Xu Y, Wang L. Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity. Radiat Oncol. 2023;18:89. https:\/\/doi.org\/10.1186\/s13014-023-02278-5.","journal-title":"Radiat Oncol"},{"key":"2561_CR7","doi-asserted-by":"publisher","first-page":"e002038","DOI":"10.1136\/jitc-2020-002038","volume":"9","author":"S Demaria","year":"2021","unstructured":"Demaria S, Guha C, Schoenfeld J, Morris Z, Monjazeb A, Sikora A, et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 2021;9:e002038. https:\/\/doi.org\/10.1136\/jitc-2020-002038.","journal-title":"J Immunother Cancer"},{"key":"2561_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cllc.2021.08.006","volume":"23","author":"JN LeClair","year":"2022","unstructured":"LeClair JN, Merl MY, Cohenuram M, Luon D. Real-world incidence of Pneumonitis in patients receiving Durvalumab. Clin Lung Cancer. 2022;23:34\u201342. https:\/\/doi.org\/10.1016\/j.cllc.2021.08.006.","journal-title":"Clin Lung Cancer"},{"key":"2561_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10637-020-01060-8","volume":"39","author":"T Sugimoto","year":"2021","unstructured":"Sugimoto T, Fujimoto D, Sato Y, Tamiya M, Yokoi T, Tamiya A, et al. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. Invest New Drugs. 2021;39:853\u20139. https:\/\/doi.org\/10.1007\/s10637-020-01060-8.","journal-title":"Invest New Drugs"},{"key":"2561_CR10","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III non\u2013small-cell Lung Cancer. N Engl J Med. 2017;377:1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"key":"2561_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","volume":"18","author":"N Shaverdian","year":"2017","unstructured":"Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18:895\u2013903. https:\/\/doi.org\/10.1016\/S1470-2045(17)30380-7.","journal-title":"Lancet Oncol"},{"key":"2561_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with Anti-programmed Death-1\/Programmed death Ligand 1 therapy. J Clin Oncol. 2017;35:709\u201317. https:\/\/doi.org\/10.1200\/JCO.2016.68.2005.","journal-title":"J Clin Oncol"},{"key":"2561_CR13","doi-asserted-by":"publisher","first-page":"e25665","DOI":"10.7759\/cureus.25665","volume":"14","author":"M Aiad","year":"2022","unstructured":"Aiad M, Fresco K, Prenatt Z, Tahir A, Ramos-Feliciano K, Stoltzfus J, et al. Comparison of Pneumonitis Rates and Severity in patients with Lung Cancer treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy. Cureus. 2022;14:e25665. https:\/\/doi.org\/10.7759\/cureus.25665.","journal-title":"Cureus"},{"key":"2561_CR14","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/cam4.3718","volume":"10","author":"Y Geng","year":"2021","unstructured":"Geng Y, Zhang Q, Feng S, Li C, Wang L, Zhao X, et al. Safety and efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Med. 2021;10:1222\u201339. https:\/\/doi.org\/10.1002\/cam4.3718.","journal-title":"Cancer Med"},{"key":"2561_CR15","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.21873\/invivo.12644","volume":"35","author":"S Watanabe","year":"2021","unstructured":"Watanabe S, ogino I, Shigenaga D, Hata M. Relationship between Radiation Pneumonitis following definitive Radiotherapy for Non-small Cell Lung Cancer and Isodose Line. Vivo. 2021;35:3441\u20138. https:\/\/doi.org\/10.21873\/invivo.12644.","journal-title":"Vivo"},{"key":"2561_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ijrobp.2022.06.068","volume":"114","author":"MC Korpics","year":"2022","unstructured":"Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, et al. Predictors of Pneumonitis in Combined thoracic stereotactic body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022;114:645\u201354. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.06.068.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2561_CR17","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1088\/0031-9155\/50\/12\/011","volume":"50","author":"H Wang","year":"2005","unstructured":"Wang H, Dong L, O\u2019Daniel J, Mohan R, Garden AS, Ang KK, et al. Validation of an accelerated demons algorithm for deformable image registration in radiation therapy. Phys Med Biol. 2005;50:2887\u2013905. https:\/\/doi.org\/10.1088\/0031-9155\/50\/12\/011.","journal-title":"Phys Med Biol"},{"key":"2561_CR18","doi-asserted-by":"publisher","first-page":"01TR01","DOI":"10.1088\/1361-6560\/aaf26a","volume":"64","author":"SJ McMahon","year":"2018","unstructured":"McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol. 2018;64:01TR01. https:\/\/doi.org\/10.1088\/1361-6560\/aaf26a.","journal-title":"Phys Med Biol"},{"key":"2561_CR19","unstructured":"Matlab. MATLAB, Version R2020a 2020."},{"key":"2561_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.radonc.2019.07.008","volume":"142","author":"RJ Klement","year":"2020","unstructured":"Klement RJ, Sonke J-J, Allg\u00e4uer M, Andratschke N, Appold S, Belderbos J, et al. Estimation of the \u03b1\/\u03b2 ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. Radiother Oncol. 2020;142:210\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2019.07.008.","journal-title":"Radiother Oncol"},{"key":"2561_CR21","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). | Protocol Development | CTEP 2022. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm (accessed March 28, 2022)."},{"key":"2561_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/CMAR.S136818","volume":"9","author":"S Chuzi","year":"2017","unstructured":"Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017;9:207\u201313. https:\/\/doi.org\/10.2147\/CMAR.S136818.","journal-title":"Cancer Manag Res"},{"key":"2561_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of Immune-related adverse events in Advanced Melanoma patients treated with Ipilimumab. Cancer Immunol Res. 2015;3:1185\u201392. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0102.","journal-title":"Cancer Immunol Res"},{"key":"2561_CR24","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2217\/fon-2019-0102","volume":"15","author":"T Baba","year":"2019","unstructured":"Baba T, Sakai F, Kato T, Kusumoto M, Kenmotsu H, Sugiura H, et al. Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. Future Oncol. 2019;15:1911\u201320. https:\/\/doi.org\/10.2217\/fon-2019-0102.","journal-title":"Future Oncol"},{"key":"2561_CR25","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/j.cllc.2019.02.018","volume":"20","author":"KR Voong","year":"2019","unstructured":"Voong KR, Hazell SZ, Fu W, Hu C, Lin CT, Ding K, et al. Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2019;20:e470\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2019.02.018.","journal-title":"Clin Lung Cancer"},{"key":"2561_CR26","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","volume":"13","author":"K Suresh","year":"2018","unstructured":"Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, et al. Pneumonitis in Non-small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors. J Thorac Oncol. 2018;13:1930\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2035.","journal-title":"J Thorac Oncol"},{"key":"2561_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40425-019-0583-3","volume":"7","author":"JD Schoenfeld","year":"2019","unstructured":"Schoenfeld JD, Nishino M, Severgnini M, Manos M, Mak RH, Hodi FS. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019;7:112. https:\/\/doi.org\/10.1186\/s40425-019-0583-3.","journal-title":"J Immunother Cancer"},{"key":"2561_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/CJI.0000000000000198","volume":"41","author":"F Manapov","year":"2018","unstructured":"Manapov F, Roengvoraphoj O, Dantes M, Marschner S, Li M, Eze C. Pneumonitis in irradiated lungs after Nivolumab: a brief communication and review of the literature. J Immunother. 2018;41:96\u20139. https:\/\/doi.org\/10.1097\/CJI.0000000000000198.","journal-title":"J Immunother"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-024-02561-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T03:02:45Z","timestamp":1732244565000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-024-02561-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2561"],"URL":"https:\/\/doi.org\/10.1186\/s13014-024-02561-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4014140\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Institutional Review Board with the ethical vote number 149\/21 S-SR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent about radiotherapy was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}